001     128073
005     20240228145532.0
024 7 _ |a 10.1007/s00401-017-1710-1
|2 doi
024 7 _ |a pmid:28401334
|2 pmid
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:18731999
|2 altmetric
037 _ _ |a DKFZ-2017-04095
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 0
|e First author
|u dkfz
245 _ _ |a H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.
260 _ _ |a Berlin
|c 2017
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1660811811_27718
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Pediatric glioblastoma (pedGBM) is an extremely aggressive pediatric brain tumor, accounting for ~6% of all central nervous system neoplasms in children. Approximately half of pedGBM harbor recurrent somatic mutations in histone 3 variants or, infrequently, IDH1/2. The remaining subset of pedGBM is highly heterogeneous, and displays a variety of genomic and epigenetic features. In the current study, we aimed to further stratify an H3-/IDH-wild type (wt) pedGBM cohort assessed through genome-wide molecular profiling. As a result, we identified three molecular subtypes of these tumors, differing in their genomic and epigenetic signatures as well as in their clinical behavior. We designated these subtypes pedGBM_MYCN (enriched for MYCN amplification), pedGBM_RTK1 (enriched for PDGFRA amplification) and pedGBM_RTK2 (enriched for EGFR amplification). These molecular subtypes were associated with significantly different outcomes, i.e. pedGBM_RTK2 tumors show a significantly longer survival time (median OS 44 months), pedGBM_MYCN display extremely poor outcomes (median OS 14 months), and pedGBM_RTK1 tumors harbor an intermediate prognosis. In addition, the various molecular subtypes of H3-/IDH-wt pedGBM were clearly distinguishable from their adult counterparts, underlining their biological distinctiveness. In conclusion, our study demonstrates significant molecular heterogeneity of H3-/IDH-wt pedGBM in terms of DNA methylation and cytogenetic alterations. The recognition of three molecular subtypes of H3-/IDH-wt pedGBM further revealed close correlations with biological parameters and clinical outcomes and may therefore, be predictive of response to standard treatment protocols, but could also be useful for stratification for novel, molecularly based therapies.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Schrimpf, Daniel
|0 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
|b 1
|u dkfz
700 1 _ |a Ryzhova, Marina
|b 2
700 1 _ |a Sturm, Dominik
|0 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
|b 3
|u dkfz
700 1 _ |a Chavez, Lukas
|0 P:(DE-He78)082dd3179733e3e716a58eb90f418a78
|b 4
|u dkfz
700 1 _ |a Hovestadt, Volker
|0 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
|b 5
|u dkfz
700 1 _ |a Sharma, Tanvi
|0 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
|b 6
|u dkfz
700 1 _ |a Habel, Antje
|0 P:(DE-He78)e1415e1a2d46648d49fa06d0c58b90df
|b 7
|u dkfz
700 1 _ |a Burford, Anna
|b 8
700 1 _ |a Jones, Chris
|b 9
700 1 _ |a Zheludkova, Olga
|b 10
700 1 _ |a Kumirova, Ella
|b 11
700 1 _ |a Kramm, Christof M
|b 12
700 1 _ |a Golanov, Andrey
|b 13
700 1 _ |a Capper, David
|0 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
|b 14
|u dkfz
700 1 _ |a von Deimling, Andreas
|0 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
|b 15
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 16
|u dkfz
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 17
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00401-017-1710-1
|g Vol. 134, no. 3, p. 507 - 516
|0 PERI:(DE-600)1458410-4
|n 3
|p 507 - 516
|t Acta neuropathologica
|v 134
|y 2017
|x 1432-0533
909 C O |p VDB
|o oai:inrepo02.dkfz.de:128073
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)a46a5b2a871859c8e2d63d2f8c666807
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)082dd3179733e3e716a58eb90f418a78
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)744146d3b5a3df1e0ac555e5bf1ee5cc
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)36e1ec4777d5b7887344177dca41eae9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)e1415e1a2d46648d49fa06d0c58b90df
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 14
|6 P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 15
|6 P:(DE-He78)a8a10626a848d31e70cfd96a133cc144
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 17
|6 P:(DE-He78)551bb92841f634070997aa168d818492
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Functional and structural genomics
|x 0
914 1 _ |y 2017
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 1
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l B062 Pädiatrische Neuroonkologie
|x 2
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l B060 Molekulare Genetik
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21